Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > trying to understand?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(625)
•••
Comment by KayakerBCon Apr 21, 2022 1:42pm
125 Views
Post# 34621016

RE:trying to understand?

RE:trying to understand?The news first come out after the market closed on i believe a up day to close @.26. Since that time the fierce article followed & the volume has been pretty much zero & not a soul has even hit the ask which has sit below .26 mark since the first NR- can someone help me to understand this without being a sausage or if u must - just need to understand why? Just seems odd - I would of thought a few of the more positive folks would be plucking these off like crazy- at the same time pockets might be filled up regardless of the low SP.

I'll repeat what I said a week ago. Lack of interest is no surprise.  The market doesn't get excited about what might happen somewhere down the road.  The J&J deal is good but for unknown drugs on an unknown time frame.  The Fierce Pharma article doesn't change that.  IMO it will take news of an imminent clinical trial, or possibly a deal with big up-front $$$ or a big milestone payment to generate any excitement.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities